Key Takeaways
- • IM8, a longevity-focused vitamin drink startup co-founded by David Beckham and CEO Danny Yeung, secured $1 billion in growth financing from General Catalyst's Customer Value Fund (CVF) as of July 2026.
- • IM8 is generating $17 million in monthly recurring revenue through a subscription-based model, demonstrating predictable cash flows that align with CVF's non-traditional lending structure.
- • General Catalyst's CVF provides structured capital via revenue-based financing rather than equity investment, meaning Beckham's Prenetics retains full ownership and avoids equity dilution while repaying the loan plus a capped percentage of customer-generated revenue.
- • The CVF loan finances up to 70% of IM8's customer acquisition costs, with General Catalyst receiving a revenue share from newly acquired customers until capital recovery and cap achievement, after which all subsequent revenue flows to Prenetics.
- • IM8 is a subsidiary of Prenetics, the health company co-founded by Yeung that went public in 2022, positioning the capital injection as a growth acceleration vehicle for a scaled wellness brand within an established public entity.
Summary
IM8, David Beckham's health drink startup focused on longevity compounds, has closed $1 billion in growth financing from General Catalyst's Customer Value Fund, marking a significant capital injection for the supplement brand. The company, which generates $17 million in monthly revenue through subscription sales, met the CVF's investment criteria of demonstrating predictable and scalable revenue streams. IM8 is a subsidiary of Prenetics, the publicly listed health company founded by CEO Danny Yeung in 2022.
The financing structure differs materially from traditional venture equity. CVF operates as a revenue-based financing provider rather than a conventional venture capital fund, meaning General Catalyst does not acquire an equity stake in IM8 and Prenetics' ownership structure remains undiluted. Instead, the $1 billion functions as a loan structured to repay the principal amount plus a capped percentage of revenue generated from customers acquired with the capital. This approach suits companies with predictable revenue models and clear paths to growth acceleration.
The capital deployment is specifically engineered to finance up to 70% of IM8's customer acquisition costs. General Catalyst receives a share of what it terms "reference income"—defined as revenue from newly acquired customers multiplied by a fixed gross-margin assumption. Once the investor recovers its principal investment and reaches its revenue-share cap, all subsequent revenue from those customer cohorts flows entirely to Prenetics. This structure aligns the investor's returns with actual customer economics while preserving the upside for the underlying business.
IM8 sells a subscription-based vitamin drink formulated with compounds linked to longevity, including ingredients such as açai fruit extract and Coenzyme Q10. The company's positioning within the broader wellness category and demonstrated monthly recurring revenue of $17 million underscore the brand's market traction prior to this capital raise. The investment follows General Catalyst's comparable $1 billion CVF commitment to Grammarly in May 2025, prior to Grammarly's acquisition of Superhuman, establishing a precedent for the fund's appetite for scaled, revenue-generating companies seeking growth acceleration capital.
The financing structure differs materially from traditional venture equity. CVF operates as a revenue-based financing provider rather than a conventional venture capital fund, meaning General Catalyst does not acquire an equity stake in IM8 and Prenetics' ownership structure remains undiluted. Instead, the $1 billion functions as a loan structured to repay the principal amount plus a capped percentage of revenue generated from customers acquired with the capital. This approach suits companies with predictable revenue models and clear paths to growth acceleration.
The capital deployment is specifically engineered to finance up to 70% of IM8's customer acquisition costs. General Catalyst receives a share of what it terms "reference income"—defined as revenue from newly acquired customers multiplied by a fixed gross-margin assumption. Once the investor recovers its principal investment and reaches its revenue-share cap, all subsequent revenue from those customer cohorts flows entirely to Prenetics. This structure aligns the investor's returns with actual customer economics while preserving the upside for the underlying business.
IM8 sells a subscription-based vitamin drink formulated with compounds linked to longevity, including ingredients such as açai fruit extract and Coenzyme Q10. The company's positioning within the broader wellness category and demonstrated monthly recurring revenue of $17 million underscore the brand's market traction prior to this capital raise. The investment follows General Catalyst's comparable $1 billion CVF commitment to Grammarly in May 2025, prior to Grammarly's acquisition of Superhuman, establishing a precedent for the fund's appetite for scaled, revenue-generating companies seeking growth acceleration capital.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.